ALK-Abelló A/S (ALK-B.CO) stock analysis

In our weekly check, ALK-Abelló A/S is graded A (A to F). Of 25 checks on debt, profit, cash flow and trend: 22 pass, warnings: 1, red flags: 2.

About ALK-Abelló A/S

ALK-Abelló A/S is a Healthcare company (Biotechnology) based in Denmark, listed on CPH as ALK-B.CO.

What our checks show for ALK-B.CO

Red flags

• The stock has fallen as much as 82% from a peak. Would you have held through that?
• Recovering from its deepest fall took about 7.6 years.

Warning signs

• Thinly traded (about 230 thousand shares a day): buying and selling can move the price.

Strengths

• Debt is low: 0.06x equity.
• Operating profit covers interest 456 times over.
• The net margin rose by 14.3 points over 5 years, to 19.9%.
• The gross margin is 68% and has risen by 6.8 points: pricing power is holding.
• Operating cash flow is 1.59x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 13.8% a year over the next years.

Next earnings report: 2026-11-17

Similar companies

ARGX · UCB.BR · LONN.SW · RVMDW · 9926.HK · ONC

Questions

What grade does ALK-Abelló A/S (ALK-B.CO) have?

In our weekly check, ALK-Abelló A/S is graded A (A to F). Of 25 checks on debt, profit, cash flow and trend: 22 pass, warnings: 1, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of ALK-B.CO stock?

This week's biggest flags for ALK-Abelló A/S: Deep past fall, Slow recovery after falls, Thinly traded. In total 3 of 25 checks show a warning or a red flag.

What does ALK-Abelló A/S do?

ALK-Abelló A/S is a Healthcare company (Biotechnology) based in Denmark, listed on CPH as ALK-B.CO.

When does ALK-Abelló A/S report earnings next?

The next earnings report is expected on 2026-11-17. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis